Loading…
Aquestive Therapeutics, Inc. is projected to rise to $4.88 by 2027, a +19% move from its current price of $4.12. AQST is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $4.00 | $4.12 | $4.24 | +0.01% |
| Jul 13 | $3.95 | $4.12 | $4.30 | +0.02% |
| Jul 14 | $3.91 | $4.12 | $4.34 | +0.03% |
| Jul 15 | $3.88 | $4.12 | $4.37 | +0.04% |
| Jul 16 | $3.86 | $4.12 | $4.41 | +0.05% |
| Jul 17 | $3.83 | $4.12 | $4.43 | +0.06% |
| Jul 18 | $3.81 | $4.12 | $4.46 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.81 | $4.12 | $4.46 | +0.07% |
| Week 2 | $3.69 | $4.13 | $4.61 | +0.13% |
| Week 3 | $3.60 | $4.13 | $4.73 | +0.20% |
| Week 4 | $3.53 | $4.13 | $4.83 | +0.26% |
| Week 5 | $3.47 | $4.13 | $4.93 | +0.33% |
| Week 6 | $3.41 | $4.14 | $5.02 | +0.39% |
| Week 7 | $3.36 | $4.14 | $5.10 | +0.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aquestive Therapeutics, Inc. is a pharmaceutical company based in Warren, New Jersey. It operates in the United States and internationally, developing and commercializing a portfolio of film-formulation medicines.
The company markets Libervant, a buccal soluble film formulation of diazepam for seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam for seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an FDA-approved, once-daily product for ADHD in patients age 6 years or older. The company’s proprietary pipeline includes Anaphylm, an epinephrine sublingual film in phase 3 for emergency treatment of allergies including anaphylaxis, and AQST-108, a topical gel in phase 2 for alopecia areata. It also develops PharmFilm technology and Adrenaverse, an epinephrine prodrug platform.
The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQST is a healthcare stock trading at $4.12 per share with a market capitalization of $516.92M and a rank of 3008 by market cap. The near-term price landscape shows a neutral stance with a 30-day trading range of $3.39 to $5.01 and a volatility profile around 60%. The stock’s technicals show a 50-day SMA of $4.23 and a 200-day SMA of $4.85, with support at $3.91 and resistance at $5.03.
A major floor 21.5% below — a decisive break under it would weaken the trend.
The nearest floor, 5.1% below — buyers have tended to step in here.
The nearest ceiling, 22.1% above — a clean break opens room to run.
A major ceiling 32.8% above — clearing it would confirm fresh momentum.
Key AQST support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AQST market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.25 | Sell | $4.22 | Sell |
| MA 10 | $4.24 | Sell | $4.27 | Sell |
| MA 20 | $4.38 | Sell | $4.29 | Sell |
| MA 50 | $4.23 | Sell | $4.25 | Sell |
| MA 100 | $4.17 | Sell | $4.30 | Sell |
| MA 200 | $4.85 | Sell | $4.37 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.14 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -82.78 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -18.09 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.15 | Buy |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 42.96 | Neutral |
| Momentum (10) | -0.35 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 4.25 | Sell |
| ADX (14) | 11.77 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is neutral, with RSI(14) at 40 indicating modest momentum. The stock trades around its 50-day moving average at $4.23 and below its 200-day moving average of $4.85, suggesting a choppy intermediate trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.95 | $4.12 | $5.68 | 0% | Neutral | |
| $3.85 | $4.88 | $6.56 | +19% | Neutral | |
| $4.37 | $5.70 | $7.97 | +38% | Bullish | |
| $4.23 | $5.67 | $8.17 | +38% | Bullish | |
| $4.63 | $6.35 | $9.40 | +54% | Bullish | |
| $6.05 | $8.47 | $12.83 | +106% | Bullish | |
| $6.69 | $9.54 | $14.74 | +132% | Bullish | |
| $7.28 | $10.57 | $16.65 | +157% | Bullish | |
| $7.84 | $11.58 | $18.54 | +181% | Bullish | |
| $7.81 | $11.73 | $19.08 | +185% | Bullish | |
| $12.38 | $20.04 | $34.81 | +387% | Bullish | |
| $18.89 | $34.85 | $66.55 | +746% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.95 | $4.12 | $5.05 | +0.00% |
| August 2026 | $3.58 | $4.24 | $5.16 | +2.96% |
| September 2026 | $3.48 | $4.16 | $5.12 | -2.05% |
| October 2026 | $3.54 | $4.25 | $5.29 | +2.39% |
| November 2026 | $3.69 | $4.45 | $5.59 | +4.64% |
| December 2026 | $3.70 | $4.49 | $5.68 | +0.95% |
Click any year to see its month-by-month AQST forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The AQST price prediction for 2026 points to an average of $4.12 (low $2.95, high $5.68) — a potential gain of 0% on today's $4.12. Price action looks broadly range-bound.
In 2027, AQST is projected to trade between $3.85 and $6.56, averaging $4.88 — a potential gain of +19% from today's $4.12. That is up +19% on the projected 2026 average. A consolidation phase looks the most probable path here.
Aquestive Therapeutics, Inc.'s 2028 outlook centres on $5.70, within a $4.37 to $7.97 range. That is up +17% on the projected 2027 average. That marks a +38% change versus current levels. Momentum favours further upside here.
By 2029, AQST could reach as high as $8.17, with a base case around $5.67 and support toward $4.23 — roughly +38% from $4.12. Buyers look set to stay in control over this stretch.
Expect AQST to range from $4.63 to $9.40 through 2030. The $6.35 average target implies a +54% move from current prices. That is up +12% on the projected 2029 average. Momentum favours further upside here.
The AQST price prediction for 2031 points to an average of $8.47 (low $6.05, high $12.83) — a potential gain of +106% on today's $4.12. Buyers look set to stay in control over this stretch.
In 2032, AQST is projected to trade between $6.69 and $14.74, averaging $9.54 — a potential gain of +132% from today's $4.12. That is up +13% on the projected 2031 average. Momentum favours further upside here.
Aquestive Therapeutics, Inc.'s 2033 outlook centres on $10.57, within a $7.28 to $16.65 range. That is up +11% on the projected 2032 average. That marks a +157% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, AQST could reach as high as $18.54, with a base case around $11.58 and support toward $7.84 — roughly +181% from $4.12. Momentum favours further upside here.
Expect AQST to range from $7.81 to $19.08 through 2035. The $11.73 average target implies a +185% move from current prices. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The AQST price prediction for 2040 points to an average of $20.04 (low $12.38, high $34.81) — a potential gain of +387% on today's $4.12. Momentum favours further upside here.
In 2050, AQST is projected to trade between $18.89 and $66.55, averaging $34.85 — a potential gain of +746% from today's $4.12. That is up +74% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AQST today (≈ 242.718447 AQST) could be worth
$8,458.51
+$7,458.51 (+746%) by 2050 · US Dollar
Based on the average projected AQST price of $34.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AQSTwould be worth at today's price.
$1,000 invested in AQST on Jul 10, 2025 (≈ 248.138945 AQST) would be worth
$1,022.33
+$22.33 (+2.2%) today · 1.02× · US Dollar
Based on a AQST entry price of $4.03 vs. today's $4.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.18 | $985.65 | -1.4% |
| 1 month ago | $3.99 | $1,032.58 | +3.3% |
| 3 months ago | $4.08 | $1,009.8 | +1.0% |
| 6 months ago | $3.51 | $1,173.79 | +17.4% |
| 1 year ago | $4.03 | $1,022.33 | +2.2% |
| All time (5.0y) ago | $3.77 | $1,092.84 | +9.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AQST forecast.
Our base-case forecast reaches $8.20 around 2031.
Implied market cap at $8.20: $1.03B
The multi-year forecast shows a rising trajectory in average price from 2026 onward. 2026: avg $4.12, min $2.95, max $5.68, ROIPct 0, sentiment NEUTRAL. 2027: avg $4.88, min $3.85, max $6.56, ROIPct 18.5, sentiment NEUTRAL.
2028: avg $5.70, min $4.37, max $7.97, ROIPct 38.4, sentiment BULLISH. 2029: avg $5.67, min $4.23, max $8.17, ROIPct 37.5, sentiment BULLISH. 2030: avg $6.35, min $4.63, max $9.40, ROIPct 54, sentiment BULLISH.
2031: avg $8.47, min $6.05, max $12.83, ROIPct 105.6, sentiment BULLISH. 2032: avg $9.54, min $6.69, max $14.74, ROIPct 131.5, sentiment BULLISH. 2033: avg $10.57, min $7.28, max $16.65, ROIPct 156.7, sentiment BULLISH.
2034: avg $11.58, min $7.84, max $18.54, ROIPct 181, sentiment BULLISH. 2035: avg $11.73, min $7.81, max $19.08, ROIPct 184.7, sentiment BULLISH. 2040: avg $20.04, min $12.38, max $34.81, ROIPct 386.5, sentiment BULLISH.
2050: avg $34.85, min $18.89, max $66.55, ROIPct 745.9, sentiment BULLISH. These figures imply a strong bullish trend in the longer horizon, though they are estimates and not guaranteed.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $6.35, with a minimum of $4.63 and a maximum of $9.40; ROIPct is 54 and the sentiment is BULLISH.
The long-run forecast presents a bullish path from 2028 through 2050, with rising average prices and positive ROI figures (e.g., 2028 ROI 38.4 and 2030 ROI 54). The near term is neutral, with current price around $4.12 and a 30-day range of $3.39 to $5.01, so outcomes are not guaranteed.
Yes, the forecast shows higher price targets beyond $12 in the later years: 2031 max is $12.83 and 2032 max is $14.74, indicating potential for gains past the $12 level.
AQST’s current price is $4.12 per share and its market capitalization is $516.92M.
Key long-term anchors include 2040 avg $20.04 and 2050 avg $34.85, with corresponding max forecasts of $34.81 and $66.55 and bullish sentiment. These figures illustrate potential substantial upside, but remain estimates and not guarantees.
Aquestive Therapeutics, Inc. Community Discussion
0Share your Aquestive Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.